Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and BCG for High-Risk NMIBC and NMI-UTUCC
NCT03504163Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2018
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in bladder cancer and upper tract urothelial carcinoma (UTUC) (2 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Proportion of patients who are disease-free at 6 months. Started Jun 2018; status: active, not recruiting.
02
Drugs
03
Conditions
bladder cancerupper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT03504163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504163.